Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
RXRX has reported updated data from its ELUCIDATE and TUPELO trials, but the stock has failed to mount a sustained rally. The ELUCIDATE update provides just an additional 10 patients of data treated ...
In The Descent, an outdoor adventure goes terribly wrong for six friends who enter caves looking for fun but find murderous creatures within the depths. Jen Karner has spent the last 10 years covering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results